Cancer cell metabolism: Implications for therapeutic targets

Experimental and Molecular Medicine

Volumn 45, Issue 10, 2013, Pages

  Jang, Miran ^a   Kim, Sung Soo ^a   Lee, Jinhwa ^b  

^a Kyung Hee University Hospital   (South Korea)

^b Dongseo University   (South Korea)

Author keywords

aerobic glycolysis; cancer; metabolism; Warburg effect

Indexed keywords

3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; 6 PHOSPHOFRUCTOKINASE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BROMOPYRUVIC ACID; C 75; DEOXYGLUCOSE; DICHLOROACETIC ACID; ENDOPEPTIDASE LA; FX 11; GLUCOSE; GLUTAMINASE; GLUTAMINE; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR; LACTATE DEHYDROGENASE; LONIDAMINE; MAMMALIAN TARGET OF RAPAMYCIN; OXAMIC ACID; PACLITAXEL; PHLORETIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE KINASE; UNCLASSIFIED DRUG; WZB 117;

ANAEROBIC GLYCOLYSIS; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL METABOLISM; ENZYME ACTIVITY; ENZYME REPRESSION; GENE MUTATION; GLUCOSE TRANSPORT; HUMAN; LIVER TOXICITY; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; PROSTATE HYPERTROPHY; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARCINOGENESIS; DRUG EFFECTS; GLYCOLYSIS; METABOLISM; NEOPLASMS; DRUG EFFECT; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; GLYCOLYSIS; HUMANS; NEOPLASMS;

EID: 84890159876     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.85     Document Type: Review

References (96)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
2. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
3. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
4. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11: 325-337.
5. Simonnet H, Alazard N, Pfeiffer K, Gallou C, Beroud C, Demont J et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 2002; 23: 759-768.
6. Weinhouse S. The Warburg hypothesis fifty years later. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1976; 87: 115-126.
7. Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) 2011; 89: 205-212.
8. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4: e532.
9. Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-producing pathways. Science 2001; 292: 504-507.
10. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64: 3892-3899.
11. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340-1344.
12. Bayley JP, Devilee P. The Warburg effect in 2012. Curr Opin Oncol 2012; 24: 62-67.
13. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010; 20: 87-90.
14. Robey RB, Hay N. Is Akt the Warburg kinase-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 2009; 19: 25-31.
15. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-713.
16. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40: 294-309.
17. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010; 39: 171-183.
18. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774.
19. Yecies JL, Manning BD. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl) 2011; 89: 221-228.
20. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010; 20: 51-56.
21. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-185.
22. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3: 187-197.
23. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 2008; 283: 28106-28114.
24. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006; 16: 253-264.
25. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007; 27: 7381-7393.
26. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008; 8: 51-56.
27. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-765.
28. Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O'Donnell KA et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 2005; 25: 6225-6234.
29. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 2008; 105: 18782-18787.
30. Hu S, Balakrishnan A, Bok RA, Anderton B, Larson PE, Nelson SJ et al. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab 2011; 14: 131-142.
31. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 2009; 9: 691-700.
32. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-120.
33. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O et al. p53 regulates mitochondrial respiration. Science 2006; 312: 1650-1653.
34. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287: 848-851.
35. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000; 26: 268-270.
36. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69: 49-54.
37. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30: 406-410.
38. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
39. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
40. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-265.
41. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207: 339-344.
42. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
43. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744.
44. Bayley JP, Devilee P. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree? Curr Opin Genet Dev 2010; 20: 324-329.
45. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011; 43: 869-874.
46. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011; 476: 346-350.
47. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S et al. Glycine decarboxylase activity drives non-small cell lung cancer tumorinitiating cells and tumorigenesis. Cell 2012; 148: 259-272.
48. Lopez-Lazaro M. Does hypoxia really control tumor growth? Cell Oncol 2006; 28: 327-329.
49. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 2006; 66: 5216-5223.
50. Lopez-Lazaro M. Why do tumors metastasize? Cancer Biol Ther 2007; 6: 141-144.
51. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-4646.
52. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004; 64: 31-34.
53. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65: 613-621.
54. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002; 62: 3909-3913.
55. Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009; 113: 2014-2021.
56. Del Bufalo D, Biroccio A, Soddu S, Laudonio N, D'Angelo C, Sacchi A et al. Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J Clin Invest 1996; 98: 1165-1173.
57. Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK. Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. Life Sci 2002; 71: 2729-2740.
58. Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX et al. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 1999; 18: 2537-2546.
59. Brawer MK. Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol 2005; 7 (Suppl 7), S21-S26.
60. Ditonno P, Battaglia M, Selvaggio O, Garofalo L, Lorusso V, Selvaggi FP. Clinical evidence supporting the role of Lonidamine for the treatment of BPH. Rev Urol 2005; 7 (Suppl 7), S27-S33.
61. Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 2007; 39: 1358-1366.
62. Lopez-Lazaro M. HIF-1: hypoxia-inducible factor or dysoxia-inducible factor? FASEB J 2006; 20: 828-832.
63. Erecinska M, Deas J, Silver IA. The effect of pH on glycolysis and phosphofructokinase activity in cultured cells and synaptosomes. J Neurochem 1995; 65: 2765-2772.
64. Trivedi B, Danforth WH. Effect of pH on the kinetics of frog muscle phosphofructokinase. J Biol Chem 1966; 241: 4110-4112.
65. Reshkin SJ, Bellizzi A, Caldeira S, Albarani V, Malanchi I, Poignee M et al. Na\+/H\+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 2000; 14: 2185-2197.
66. Harguindey S, Orive G, Luis Pedraz J, Paradiso A, Reshkin SJ. The role of pH dynamics and the Na\+/H\+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin-one single nature. Biochim Biophys Acta 2005; 1756: 1-24.
67. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na\+/H\+ exchanger in metastasis. Nat Rev Cancer 2005; 5: 786-795.
68. Evans DM, Sloan-Stakleff K, Arvan M, Guyton DP. Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride. Clin Exp Metastasis 1998; 16: 353-357.
69. Sparks RL, Pool TB, Smith NK, Cameron IL. Effects of amiloride on tumor growth and intracellular element content of tumor cells in vivo. Cancer Res 1983; 43: 73-77.
70. Garber K. Energy deregulation: licensing tumors to grow. Science 2006; 312: 1158-1159.
71. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005; 8: 311-321.
72. Li JJ, Wang H, Tino JA, Robl JA, Herpin TF, Lawrence RM et al. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett 2007; 17: 3208-3211.
73. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233.
74. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15: 300-308.
75. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
76. Fang M, Shen Z, Huang S, Zhao L, Chen S, Mak TW et al. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 2010; 143: 711-724.
77. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 1991; 266: 4706-4712.
78. Eigenbrodt E, Mazurek S, Grimm H Use of sugar phosphates, sugar phosphate analogs, amino acids and/or amino acid analogs for modulating the glucolysis-enzyme complex, the malate aspartate shuttle and/or the transaminases 2009. US20090163591.
79. Scheefers H Compounds for modulating the glycolysis enzyme complex and/or the transaminase complex 2009. US20090149415.
80. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18: 207-219.
81. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9: 425-434.
82. Bui T, Thompson CB. Cancer's sweet tooth. Cancer Cell 2006; 9: 419-420.
83. Deck LM, Royer RE, Chamblee BB, Hernandez VM, Malone RR, Torres JE et al. Selective inhibitors of human lactate dehydrogenases and lactate dehydrogenase from the malarial parasite Plasmodium falciparum. J Med Chem 1998; 41: 3879-3887.
84. Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxolresistant cancer cells to taxol. Mol Cancer 2010; 9: 33.
85. Stacpoole PW, Gilbert LR, Neiberger RE, Carney PR, Valenstein E, Theriaque DW et al. Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics 2008; 121: e1223-e1228.
86. Stacpoole PW, Kurtz TL, Han Z, Langaee T. Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv Drug Deliv Rev 2008; 60: 1478-1487.
87. Griguer CE, Oliva CR, Gillespie GY. Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J Neurooncol 2005; 74: 123-133.
88. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490.
89. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008; 8: 967-975.
90. Berridge MV, Herst PM, Tan AS. Metabolic flexibility and cell hierarchy in metastatic cancer. Mitochondrion 2010; 10: 584-588.
91. Chen JL, Lucas JE, Schroeder T, Mori S, Wu J, Nevins J et al. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet 2008; 4: e1000293.
92. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010; 1805: 105-117.
93. Wu CH, Ho YS, Tsai CY, Wang YJ, Tseng H, Wei PL et al. In vitro and in vivo study of phloretin-induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter. Int J Cancer 2009; 124: 2210-2219.
94. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H et al. A smallmolecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 2012; 11: 1672-1682.
95. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010; 107: 2037-2042.
96. Vazquez-Martin A, Colomer R, Brunet J, Menendez JA. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin) by transcriptionally inhibiting 'HER2 superexpression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int J Oncol 2007; 31: 769-776.